text:
Kent Laboratory - Blog
Head of Unit
Professor Stephen Kent
E: email@example.com
Location: Level 7, Rm 7064, Peter Doherty Institute for Infection & Immunity, Parkville
W: Personal web page
An HIV vaccine is urgently needed. The Kent lab is working towards this goal. Our dedicated staff and students drive innovation and new thinking in ways to tackle the HIV/AIDS epidemic. Prof Kent was recently awarded the Peter Doherty Award for Outstanding PhD Supervision which reflects the quality of our work and PhD students in this area.
The HIV pandemic continues to expand rapidly around the world, notably in the Asian-Pacific and Africa. Public health and economic burdens of HIV represents a major threat to regional and global security. Preventative strategies remain limited, and therapeutic options are restricted in both efficacy and implementation. The lack of an effective HIV vaccine is a catastrophic failure of our public health response to the epidemic.
Better strategies are needed to prevent HIV infection and disease. This requires an understanding of how HIV causes AIDS, including which immune responses control HIV replication and which contribute to disease. A better understanding of effective immunity will expand the pipeline to novel treatment and prevention strategies.
Despite the clear need, development of HIV-1 vaccines has proceeded for 20+ years without success. HIV has a propensity to mutate to avoid immune responses and form latent reservoirs - these are formidable challenges to developing successful vaccines. There is a palpable sense in the HIV vaccine research community that fresh innovative ideas are needed. Quantum leaps away from existing paradigms will be needed to make large inroads into defining protective immunity to HIV-1.
To further understand how immune responses can control HIV, we have a series of projects involved in developing new assays to measure immunity and the effect these immune responses have on the virus. We have recently developed a new and exciting technique to measure antibody dependent cellular cytotoxicity (ADCC). We developed a very simple assay on small volumes of blood to measure ADCC responses and are now studying how useful it is in people with HIV and whether it forces the virus to mutate to escape this potentially important response. Although T cell immunity is effective against the virus, immune escape is a hallmark of effective T cell immunity. We have developed innovative techniques to measure immune escape variants very sensitively. This allows us to study the impact of these escape mutants and whether it can force the virus into a weakened state. We have become very interested in how immune responses target the envelope protein of the virus. Surprisingly, our data to date suggests that envelope specific T cell immunity has little impact on virus replication. We are now trying to understand how neutralising antibodies and T cell immunity against envelope could help corner the virus. We also have ongoing projects studying small but important lymphocyte populations such as regulatory T cells and NKT cells . We have recently branched out into adapting some of our novel ADCC assays to understand how ADCC immunity controls influenza pandemics.
Our understanding of immune responses against the virus allows us to push on with developing novel vaccine technologies. In particular we have an exciting project studying nanoparticle vaccines where tiny capsules are loaded with vaccine antigens to protect them from degradation and target important immune cells that stimulate effective immunity. We are continuing to study aspects of overlapping peptide pulsed autologous cells (OPAL) as an effective therapeutic vaccine. We recently showed that this vaccine can delay AIDS. In addition we have exciting projects studying influenza recombinant vaccines. These flexible vaccine technologies allow us to refine our understanding of what will constitute effective immunity to HIV.
Information for Prospective Students and Staff
The Kent laboratory at the University of Melbourne has had great success in training excellent PhD and Honours students over the years. Prof Kent was honoured to receive the Peter Doherty Outstanding PhD Supervisor award from the University of Melbourne (see story here ). All our Honours students have achieved First Class Honours, and our PhD students are highly productive, producing several first- and co-authored scientific publications. The vast majority of our PhD students finish in under 3.5 years, well below the average time taken. Most of our recent Australian PhD students have received prestigious NHMRC post doctoral fellowships or similar fellowships to continue their research. Our philosophy is that it is important for students to learn to become very productive in the scientific world and to do all we can to facilitate their move to the next stage of their career. See this link for other useful advice for potential PhD students.
We are always happy to hear from potential students. Interested students should review our projects and publications pages, and email their CV and transcripts to firstname.lastname@example.com. Prospective PhD students should also see the Melbourne School of Graduate Research website for eligibility criteria and scholarship information as all our students hold prestigious PhD scholarships.
The Kent laboratory has a wide range of interesting projects that will suit dedicated and inquisitive Post-doctoral Fellows. We are interested in early stage Post-doctoral Fellows with a desire to make a difference in the HIV vaccine field. The University of Melbourne offers generous remuneration packages. More details can be found on the Human Resources website.
Recent Graduates and Post-doctoral Fellows
The Kent Laboratory is immensely proud of its former staff and students who have contributed to our research and then progressed into new fields.
Dr Sinth Jegaskanda is a recently graduated PhD student taking up a postdoc at the NIH in the USA to study influenza immunity. He was awarded both a CJ Martin NHMRC fellowship and an Australian-American fellowship to start his work. He returned to our department to work with Prof Cam Simmons in 2016.
Dr Marjon Navis is a Dutch post doc who spent just over 2 years in the Kent lab. She landed a job with a great lab at the Karolinska Insitute in Sweden in 2011 and subsequently took a job with Janssen Pharmaceuticals in 2015.
Dr Amy Chung obtained her PhD with the Kent lab in March 2011 and then held a post-doc position with Dr Galit Alter at Harvard/Ragon Institute. Amy was awarded a prestigious America-Australia Scholarship to help with her move and was also awarded an NHMRC Overseas Postdoctoral Fellowship. She has published on ADCC immunity in Science Translational Medicine and Cell with the Harvard group. She rejoined the Kent group in 2015 and has both NHMRC and amfAR funding.
Dr Liyen Loh obtained her PhD in February 2010 and was awarded an NHMRC Overseas Biomedical Postdoctoral Training Fellowship to further her career in the lab of Professor Doug Nixon at UCSF in San Francisco. During her PhD, Liyen was awarded a prestigious Commendation for the 2009 Premier's Award for Health and Medical Research. She was also awarded the QIAGEN PhD Achievement Award. Her work has been featured in The University of Melbourne Voice (May 2009). She returned to the University of Melbourne to work with Dr Katherine Kedzierska in our department.
Dr Rosemarie Mason was awarded her PhD in 2009. She initially returned to Canada to a postdoctoral position at the University of Toronto. She was offered a Marie Curie and Canadian Heart Foundation Postdoctoroal fellowships on her return to Canada. She took up a position in Dr Mario Roederer's lab at the NIH.
Dr Viv Peut obtained her PhD in December 2008, and was awarded a NHMRC Overseas based Biomedical Fellowship to further her research on HIV vaccines in the lab of Professor Julie McElrath at the Fred Hutchison Research Centre in Seattle. She returned to the University of Melbourne to work with the Turner/Doherty group, and is now working with Roy Hill mining.
Dr Ivan Stratov is an infectious diseases physician who completed a PhD with the Kent laboratory in 2006. He was awarded a prestigious NHMRC clinical fellowship to pursue his work with ADCC responses in HIV-infected people in the Kent lab. He was successful with NHMRC project grants.
Dr Miranda Smith was awarded her PhD in March 2008, and obtained a NHMRC CJ Martin Fellowship to work in the lab of Dr Annette Oxenius at the Swiss Federal Institute of Technology in Zurich. She returned to Melbourne to work with Prof Sharon Lewin at the Alfred Hospital/University of Melbourne and is now managing a large Centre of Research Excellence in Infectious Diseases.
Dr Erik Rollman spent 2.5 years with us as a Post-doctoral Fellow on a prestigious Swedish Research Council Fellowship. He returned to Sweden in 2008 to take up a position with a biotech company.
Ms Socheata Chea obtained her First-Class Honours in 2002, working with us on peptide immunotherapies. After travelling and working in the UK, she returned to Australia in 2007 to take up a position with Pfizer/Zoetis in Parkville.
Viv and Liyen
Research Facilities
Our laboratory and offices are located on the 7th floor of the Peter Doherty Institute for Infection and Immunity (PDI) on the corner of Grattan and Elizabeth Streets in Parkville. Our building, which was completed in late 2013, is a purpose built facility which provides laboratory and office space for:
- Department of Microbiology and Immunology, University of Melbourne
- Victorian Infectious Diseases Reference Laboratory
- WHO Collaborating Centre for Reference and Research on Influenza
- Microbiological Diagnostic Unit Public Health Laboratory
- Victorian Infectious Diseases Service
- Victorian Healthcare Associated Infection Surveillance System
With such interesting neighbours, it is a great place to do science. We moved to the PDI in early 2014.
Lab Facilities
Our modern HIV immunology/ virology laboratory has 70m2 of new laboratory space, 3 class II biosafety cabinets, 3 refrigerated centrifuges, 2 microscopes, 2 -70C freezers, a 30,000 viral liquid N2 storage facility, 2 CO2 incubators, ABI and Eppendorf real time PCR machines, a Coulter counter and an AID Elispot reader. The Kent group also has direct access to an adjacent PCR suite. In addition, we share a new PC3 laboratory suite located within the department. The PC3 laboratory is equipped with 3 class II biosafety cabinets, 2 CO2 incubators, an ultracentrifuge, a microscope and a flow cytometer. A new Astrios FACS sorter was installed in the PC3 lab recently.
Animal Facility
Prof Kent manages and operates a PC3 animal facility of 150m2, staffed with dedicated animal technicians. Purpose-designed cages and video surveillance are installed in all rooms. A separate laboratory with a class II biosafety cabinet and refrigerated centrifuge is also located within the animal facility. The department manages a superb mouse facility.
Flow Cytometry Facility
The Kent lab has fantastic access to a world-class flow cytometry facility located 2 floors above the lab. The facility has a dedicated manager and manages high end Fortessa, LSRII, Aria, Canto machines among others. We purchased our own Fortess in 2015.
Clinical Resources
Prof Kent sees HIV-infected adult patients at the Alfred Hospital and Melbourne Sexual Health Centre, the 2 major tertiary referral centres for HIV in Melbourne. We have ready access to samples from HIV-infected subjects, which assists our work on ADCC responses to HIV.
Computer Facilities
The Kent laboratory has numerous ethernet-linked Mac computers with Intel Core processors. We operate an electronic laboratory storage of records system, and an electronic lab book system for more efficient and secure storage of data. All computers are backed up regularly. We have purchased MacBook Pro laptops for most of our PhD students.
Major Collaborators
NHMRC Program Grant 2014 - 2018
This Program focuses on immunity to HIV in informative clinical cohorts and model systems. Our studies will guide development of novel treatments, cure strategies and vaccines through preclinical and early phase clinical investigations.
Our team includes:
Clinician-scientists with a proven record in the identification of unresolved issues in the clinic and the establishment of laboratory strategies to investigate these issues with patient samples and animal models:
Drs David Cooper, Anthony Kelleher, University of NSW
Dr Stephen Kent, University of Melbourne
Dr Sharon Lewin, Peter Doherty Institute for Infection & Immunity
A basic scientist providing expertise in immunology and virology underpinning disease pathogenesis:
Dr Damian Purcell, University of Melbourne
A clinical researcher with substantive experience in clinical research and development:
Dr Sean Emery, University of NSW
A mathematical modeller and biostatistician:
Dr Miles Davenport, University of NSW
Other co-Investigators strengthen the clinical and laboratory capacity with skilled scientists who provide the "engine-room" to drive further advances.
Australia-India Strategic Research Fund
This award from 2013-2016 supported collarboative research on HIV immunity with the group of Dr Madhur Thakar at the National AIDS Research Insitute in Pune India. We studied ADCC immunity to HIV in both cohorts of HIV+ subjects in India and Australia. We shared technology transfer of key assays in both directions. The Australian component is funded by the Australian government Department of Innovation, Industry, Science and Research.
Other Collaborations
Drs Miles Davenport and Janka Petravic, University of NSW
Dr Davenport and colleagues have been instrumental in helping refine our understanding of immune escape and reversion and HIV latency. His group brings insightful thinking and sophisticated mathematical modelling to help explain our experimental data and testable hypotheses. We have ARC and NHMRC project grants with Miles.
Drs Frank Caruso and Angus Johnston, University of Melbourne
The Caruso group from the Department of Chemical and Biomolecular Engineering are experts in layer-by-layer nanoparticles. These particles hold great potential as a vaccine delivery system. We were awarded an ARC Centre of Excellence grant with Drs Caruso and Johnston and 17 other CIs around Australia.
Dr Dale Godfrey, University of Melbourne
The Godfrey lab are leaders in the study of NKT cells and instrumental in our collaborative work in the area.
Drs Andrew Brooks , Lucy Sullivan and Jie Lin, University of Melbourne
We have been actively collaborating with the Brooks lab studying CD8 T cell immunity using MHC tetramers. We are also studying NK cell KIR ligand interactions with macaque MHC molecules.
Visit Stephen's Departmental Research Pages
Note: the following link goes to the main Departmental Website.
Journal Publications
235. Lee WS, Kristensen AB, Rasmussen TA, Tolstrup M, Østergaard L, Søgaard OS, Wines BD, Hogarth PM, Reynaldi A, Davenport M, Emery S, Amin J, Cooper DA, Kan V, Fox J, Grüll H, Parsons MS, Kent SJ. Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption. Journal of Virology 2017; In Press.
234. Vanderven HA, Liu L, Ana-Sosa-Batiz F, Nguyen TH, Wan Y, Wines B, Hogarth PM, Tilmanis D, Reynaldi A, Parsons MS, Hurt AC, Davenport MP, Kotsimbos T, Cheng AC, Kedzierska K, Zhang X, Xu J, Kent SJ. Fc functional antibodies during severe human H7N9 and seasonal influenza. JCI Insight 2017; In press.
233. Mclean MR, Madhavi V, Wines BD, Hogarth PM, Chung A, Kent SJ. Dimeric Fcγ receptor ELISA to study HIV-specific antibodies: a new look into breadth of Fcγ receptor antibodies induced by the RV144 vaccine trial. The Journal of Immunology 2017; In Press.
232. Glass JJ, Chen L, Alcantara S, Crampin EJ, Thurecht KJ, De Rose R, Kent SJ. Charge has a marked influence on hyperbranched polymer nanoparticle association in whole human blood. ACS Macro Letters 2017; 6: 586-592.
231. Parsons MS, Lloyd SB, Lee WS, Kristensen AB, Amarasena T, Center RJ, Keele BF, Lifson JD, LaBranche CC, Montefiori D, Wines BD, Hogarth PM, Swiderek KM, Venturi V, Davenport MP, Kent SJ. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Science Translational Medicine 2017; In Press.
230. Kratochvil S, McKay PF, Kopycinski JT, Bishop C, Hayes PJ, Muir L, Pinder CL, Cizmeci D, King D, Aldon Y, Wines BD, Hogarth M, Chung AW, Kent SJ, Held K, Geldmacher C, Dally L, Santos NS, Cole T, Gilmour J, Fidler S, Shattock RJ. A Phase I HIV vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens. Frontiers in Immunology 2017; In Press.
229. Jegaskanda S, Vanderven HA, Wheatley AK, Kent SJ. Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design. Human Vaccines and Immunotherapeutics 2017; ePub: 1-9.
228. Rasmussen TA, McMahon J, Chang JJ, Symons J, Roche M, Dantanarayana A, Okoye A, Hiener B, Palmer S, Lee WS, Kent SJ, Van Der Weyden C, Prince HM, Cameron PU, Lewin SR. Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. AIDS 2017; In Press.
227. Zaunders J, Xu Y, Kent SJ, Koelsch KK, Kelleher AD. Divergent expression of CXCR5 and CCR5 on CD4+ T cells and the paradoxical accumulation of T follicular helper cells during HIV infection. Frontiers in Immunology 2017; 8: Article 495.
226. Rockman S, Lowther S, Camuglia S, Vandenberg K, Taylor S, Fabri L, Miescher S, Pearse M, Middleton D, Kent SJ, Maher D. Intravenous immunoglobulin protects against severe pandemic influenza infection. EBioMedicine 2017; 19: 119-27.
225. Glass JJ, Li Y, De Rose R, Johnston A, Czuba E, Khor SY, Quinn J, Whittaker M, Davis T, Kent SJ. Thiol-Reactive Star Polymers display enhanced association with distinct human blood components. ACS Applied Materials & Interfaces 2017; 9: 12182-94.
224. Wines BD, Billings H, Mclean MR, Kent SJ, Hogarth PM. HIV-specific ADCC - new technologies to study ADCC and importance for the HIV vaccine field. Current HIV Research 2017; In Press.
223. Kent SJ. HIV Vaccine Approaches. In: eLS. 2017. (John Wiley & Sons Ltd.). In Press.
222. Madhavi V, Kulkarni A, Shete A, Lee WS, Mclean MR, Kristensen AB, Ghate M, Wines BD, Hogarth PM, Parsons MS, Kelleher AD, Cooper DA, Amin J, Emery S, Thakar M, Kent SJ. Effect of combination antiretroviral therapy on HIV-1-specific antibody-dependent cellular cytotoxicity responses in subtype B- and subtype C-infected cohorts. J AIDS 2017; In Press.
221. Kent SJ, Kelleher AD. Expanding role for Type I Interferons in restricting HIV growth. Immunology and Cell Biology 2017; 95: 417-18.
220. Petravic J, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP. Relationship between measures of HIV reactivation and the decline of latent reservoir under latency-reversing agents. J Virol 2017; 91: e02092-16.
219. Xu Y, Phetsouphanh C, Suzuki K, Aggarwal A, Graff-Dubois S, Roche M, Bailey M, Alcantara S, Flanagan S, Cash K, Siva R, Koelsch KK, Autran B, Harvey R, Gorry PR, Moris A, Cooper DA, Turville S, Kent SJ, Kelleher AD, Zaunders J. HIV-1 and SIV predominantly use CCR5 expressed on a precursor population to establish infection in T follicular helper cells. Frontiers in Immunology 2017; 8: Article 376.
218. Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CM. Cytotoxic CD4 T cells - friend or foe during viral infection? Frontiers in Immunology 2017; 8: Article 19.
217. Gause KT, Wheatley AK, Cui J, Yan Y, Kent SJ, Caruso F. Immunological principles guiding the rational design of particles for vaccine delivery. ACS Nano 2017; 11: 54-68.
216. Kulkarni A, Kurle S, Shete A, Ghate M, Godbole S, Madhavi V, Kent SJ, Paranjape R, Thakar M. Indian long-term non-progressors show broad ADCC responses with preferential recognition of V3 region of Envelope and a region of Tat protein. Frontiers in Immunology 2017; 8: 5.
215. Vanderven HA, Jegaskanda S, Wheatley AK, Kent SJ. Antibody dependent cellular cytotoxicity and influenza virus. Current Opinion in Virology 2017; 22: 89-96.
214. Selva KJ, Kent SJ, Parsons MS. Modulation of innate and adaptive cellular immunity relevant to HIV-1 vaccine design by seminal plasma. AIDS 2017; 31: 333-42.
213. Pinkevych M, Kent SJ, Tolstrup M, Lewin SR, Cooper DA, Søgaard OS, Rasmussen TA, Kelleher AD, Cromer D, Davenport MP. Modeling of experimental data supports HIV reactivation from latency after treatment interruption on average once every 5-8 days. Plos Pathogens 2016; 12: e1005740
212. Parsons MS, Richard J, Lee WS, Vanderven H, Grant MD, Finzi A, Kent SJ. NKG2D acts as a co-receptor for natural killer cell-mediated anti-HIV-1 antibody-dependent cellular cytotoxicity. AIDS Research and Human Retroviruses 2016; 32: 1089-96.
211. Munier CML, van Bockel D, Bailey M, Ip S, Xu Y, Alcantara S, Liu SM, Denyer G, Kaplan W, PHIIDO Study group, Suzuki K, Croft N, Purcell A, Tscharke D, Cooper DA, Kent SJ, Zaunders JJ, Kelleher AD. The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype. Vaccine 2016; 34: 5251-61.
210. Mann SK, Dufour A, Glass JJ, De Rose R, Kent SJ, Such GK, Johnston APR. Tuning the properties of pH responsive nanoparticles to control cellular interactions in vitro and ex vivo. Polymer Chemistry 2016; 7: 6015-24.
209. Wheatley AK, Kent SJ. Twist in the Tail: Escape from HIV neutralising antibodies at a single site confers broad susceptibility to others. EBioMedicine 2016; 12: 14-15.
208. Wines BD, Vanderven HA, Esparon SE, Kristensen AB, Kent SJ, Hogarth PM. Dimeric FcγR ectodomains as probes of the Fc-receptor function of anti-Influenza Virus IgG. The Journal of Immunology 2016; 197: 1507-16.
207. Wheatley AK, Kristensen AB, Lay WN, Kent SJ. HIV-dependent depletion of influenza-specific memory B cells may impacts B cell responsiveness to seasonal influenza immunisation. Scientific Reports 2016; 6: 26478.
206. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, Chen W, Wines B, Hogarth PM, Lambe T, Gilbert SC, Parsons MS, Kent SJ. What lies beneath: Antibody dependent natural killer cell activation by antibodies to internal influenza virus proteins. Ebiomedicine 2016; 8: 277-90.
205. Ana-Sosa-Batiz F, Vanderven H, Jegaskanda S, Johnston APR, Rockman S, Laurie K, Barr I, Reading P, Lichtfuss M, Kent SJ. Influenza-specific antibody-dependent phagocytosis. Plos One 2016; 11: e0154461.
204. Kristensen AB, Lay WN, Ana-Sosa-Batiz F, Vanderven HA, Madhavi V, Laurie KL, Carolan L, Wines BD, Hogarth M, Wheatley AK, Kent SJ. Antibody responses with Fc-mediated functions after vaccination of HIV-infected subjects with trivalent influenza vaccine. Journal of Virology 2016; 90: 5724-34.
203. Kent SJ, Kim JH. HIV vaccines moving forward. Current Opinion HIV AIDS; 11: 545.
202. Gooneratne SL, Center RJ, Kent SJ, Parsons MS. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation. Clinical & Experimental Immunology 2016; 184: 101-9.
201. Glass JJ, Yuen D, Rae J, Johnston APR, Parton RG, Kent SJ, De Rose R. Human immune cell targeting of protein nanoparticles – caveospheres. Nanoscale 2016; 8: 8255-65.
200. Glass JJ, De Rose R, Kent SJ. Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. Expert Review of Vaccines 2016; 15: 719-29.
199. Beck SE, Queen SE, Viscidi R, Johnson D, Kent SJ, Adams RJ, Tarwater PM, Mankowski JL. Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control. J Neurovirol 2016; 22: 498-507.
198. Lloyd SB, Lichtfuss M, Amarasena TH, Alcantara S, De Rose R, Tachedjian G, Alinejad-Rokny H, Venturi V, Davenport MP, Winnall WR, Kent SJ. High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. Virology 2016; 492: 1-10.
197. Tan HX, Gilbertson BP, Jegaskanda S, Alcantara S, Amarasena T, Stambas J, McAuley JL, Kent SJ, De Rose R. Recombinant Influenza Virus Expressing HIV-1 p24 Capsid Protein Induces Mucosal HIV-specific CD8 T-cell Responses. Vaccine 2016; 34: 1172-9.
196. Lee WS, Richard J, Lichtfuss M, Smith AB, Park J, Courter JR, Melillo BN, Sodroski JG, Kaufmann DE, Finzi A, Parsons MS, Kent SJ. Antibody dependent cellular cytotoxicity against reactivated HIV-1-infected cells. J Virol 2015; 90: 2021-30.
195. Parsons MS, Kent SJ. Paradox of protection: Preferential recognition of CD4-induced epitopes by anti-HIV-1 ADCC antibodies (Commentary). Ebiomedicine 2015; 2: 1298-9.
194. Kent SJ. Eradication and cure of HIV (Chapter 105). In Infectious Diseases, 2017 (4th edition, Editors Cohen, Powderly and Opal; Elsevier). pp 931-35.
193. Kent SJ*. That last knoll. Wild 2015; 150: 32-36. (*This is an article on bushwalking not a scientific article! Enjoy!).
192. Wheatley AK, Kent SJ. Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity. Expert Review of Vaccines 2015; 14: 1227-1239.
191. Parsons MS, Madhavi V, Ana-Sosa-Batiz F, Center RJ, Wilson KM, Bunupuradah T, Ruxrungtham K, Kent SJ. Seminal plasma anti-HIV antibodies trigger antibody-dependent cellular cytotoxicity: Implications for HIV transmission. J AIDS 2016; 71: 17-23.
190. Tan HX, Kent SJ, De Rose R. Contemporary HIV vaccines: tissue resident T-cells and strategies to prevent mucosal infection. Current Topics in Medicinal Chemistry 2015; 16: 1107-17.
189. Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Søgaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission. Plos Pathogens 2015; 11: e1005000.
188. Lee WS, Parsons MS, Kent SJ, Lichtfuss M. Can HIV-1-specific ADCC assist the clearance of reactivated latently infected cells? Frontiers in Immunololgy 2015; 6: Article 265.
187. Martyushev AP, Petravic J, Grimm AJ, Alinejad-Rokny H, Gooneratne SL, Reece JC, Cromer D, Kent SJ, Davenport MP. Epitope-Specific CD8+ T Cell Kinetics Rather than Viral Variability Determine the Timing of Immune Escape in Simian Immunodeficiency Virus Infection. J Immunol 2015; 194: 4112-21.
186. Kent SJ. Trying to cure HIV with immunotherapy: not so simple (commentary). The Lancet HIV 2015; 2: e72-3.
185. Insight Start Study Group (Kent SJ Investigator). Initiation of Antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.
184. Tang C-C, Isitman G, Bruneau J, Tremblay C, Bernard NF, Kent SJ, Parsons MS. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. Clinical and Experimental Immunology 2015; 181: 275-85.
183. Cui J, De Rose R, Alt K, Alcantar S, Paterson B, Liang K, Hu M, Richardso, JJ, Yan Y, Jeffery C, Price R, Peter K, Hagemeyer C, Donnelly P, Kent SJ, Caruso F. Engineering Poly(ethylene glycol) Particles for Improved Biodistribution. ACS Nano 2015; 9: 1571-80.
182. Winnall WR, Lloyd SB, De Rose R, Alcantara S, Amarasena TH, Hedger MP, Girling JE, Kent SJ. Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis. J Leuk Biol 2015; 97: 599-609.
181. Li J, Ahmet F, Sullivan LC, Brooks AG, Kent SJ, De Rose R, Salazar AM, Reis e Sousa C, Shortman K, Lahoud MH, Heath WR, Caminschi I. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol 2015; 45: 854-64.
180. Kramski M, Stratov I, Kent SJ. The role of HIV-specific ADCC in HIV prevention and the influence of the HIV-1 Vpu protein. AIDS 2015; 29: 137-44.
179. Gooneratne S, Richard J, Lee WS, Finzi A, Kent SJ, Parsons MS. Slaying the Trojan horse: Natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T-cells. J Virol 2015; 89: 97-109.
178. Gooneratne S, Alinejad-Rokny H, Ebrahimi D, Bohn PS, Wiseman RW, O'Connor DH, Davenport MP, Kent SJ. Linking pig-tailed macaque major histocompatibility complex class I haplotypes and cytotoxic T lymphocyte escape mutations in SIV infection. J Virol 2014; 88: 14310-25.
177. Petravic J, Martyushev A, Reece JC, Kent SJ, Davenport MP. Modeling the timing of anti-latency drug administration during HIV treatment. J Virol 2014; 88: 14050-6.
176. Fernandez CS, Amarasena T, Kelleher AD, Rossjohn J, McCluskey J, Godfrey DI, Kent SJ. MAIT cells are depleted early but retain functional cytokine expression in HIV infection. Immunology and Cell Biology 2014; doi: 10.1038/icb.2014.91.
175. Parsons MS, Loh L, Gooneratne S, Center RJ, Kent SJ. Role of education and differentiation in determining the potential of NK cells to respond to antibody-dependent stimulation. AIDS. 2014; 28: 2781-8.
174. Kent SJ, Davenport MP. Tentative steps to eradicate latent HIV (commentary). The Lancet HIV. 2014; 1: e2-3.
173. Madhavi V, Ana-Sosa-Batiz F, Jegaskanda S, Center RJ, Winnall WR, Parsons MS, Ananworanich J, Cooper DA, Kelleher AD, Hsu D, Pett S, Stratov I, Kramski M, Kent SJ. Antibody-dependent effector functions against HIV decline in subjects on antiretroviral therapy. Journal of Infectious Diseases. 2015; 211: 529-38.
172. Florek N, Weinfurter J, Jegaskanda S, Brewoo J, Powell T, Young G, Das S, Hatta M, Broman K, Hungnes O, Dudman S, Kawaoka Y, Kent SJ, Stinchcomb D, Osorio J, Friedrich T. Modified vaccinia Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol 2014; 88: 13418-28
171. Stratov I, Kent SJ. Antiretroviral therapy initiation in an Australian cohort - implications for increased use of antiretroviral therapy. European Journal of Clinical Microbiology and Infectious Diseases. 2015; 34: 253-259.
170. Jegaskanda S, Vandenberg K, Laurie KL, Loh L, Kramski M, Winnall WR, Kedzierska K, Rockman S, Kent SJ. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. Journal of Infectious Diseases 2014: 210: 1811-1822.
169. Jegaskanda S, Ahn SH, Skinner N, Thompson A, Ngyuen T, Holmes J, De Rose R, Navis N, Winnall WR, Kramski M, Bernardi G, Bayliss J, Colledge D, Sozzi V, Visvanathan K, Locarnini S, Kent SJ, and Revill P. Down-regulation of IL-18 mediated cell signalling and IFN-γ expression by the hepatitis B virus e antigen. J Virol 2014; 88: 10412-30.
168. De Rose R, Kent SJ, Ranasinghe C. Prime-boost vaccination: Impact on the HIV vaccine field. (Book Chapter). In Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. (eds Singh and Salnikov) Elsevier 2015, pp 289-313.
167. Ana-Sosa-Batiz F, Johnston APR, Liu H, Center RJ, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungal J, Kim JH, Michael NL, Kelleher AD, Stratov I, Kent SJ, Kramski M. HIV-specific antibody-dependent phagocytosis (ADP) matures during HIV infection. Immunology and Cell Biology 2014; 92: 679–687.
166. Madhavi V, Wren LH, Center RJ, Gonelli C, Winnall WR, Parsons MS, Kent SJ, Stratov I. Breadth of HIV-specific ADCC - Relevance to global HIV vaccine design. AIDS 2014; 28: 1859-70.
165. Winnall WR, Beasley MD, Center RJ, Parsons MS, Kiefel BR, Kent SJ. The maturation of antibody technology for the HIV epidemic. Immunology and Cell Biology 2014; 92: 570-77.
164. Jegaskanda S, Reading PC, Kent SJ. Influenza-specific ADCC – towards universal influenza vaccines. J Immunol 2014; 193: 469-75.
163. Fernandez CS, Kelleher, AD, Finlayson,R Godfrey DI, Kent SJ. NKT cell depletion in humans during early HIV-1 infection. Immunology and Cell Biology 2014; 92: 578-90.
162. Reece JC, Martyushev A, Petravic J, Grimm A, Gooneratne S, Amaresena T, De Rose R, Loh L, Davenport MP, Kent SJ. Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies. Plos One 2014; 9: e93330.
161. Trist HM, Tan PS, Wines BD, Ramsland PA, Orlowski E, Stubbs J, Gardiner EE, Pietersz GA, Kent SJ, Stratov I, Burton DR, Hogarth PM. Polymorphisms and Interspecies Differences of the activating and inhibitory FcγRII of Macaque nemestrina Influence the Binding of Human IgG Subclasses. J Immunol 2014; 192: 792-803.
160. Parsons MS, Tang C-C, Jegaskanda S, Center RJ, Brooks AG, Stratov I, Kent SJ. Anti-human immunodeficiency virus antibody-dependent cellular cytotoxicity impairs natural killer cell NKp46 expression. J Immunol 2014; 192: 308-315.
159. Jegaskanda S, Amarasena T, Laurie KL, Tan H-X, Butler J, Parsons MS, Alcantara S, Petravic J, Davenport MP, Hurt A, Reading PC, Kent SJ. Standard trivalent influenza protein vaccination does not prime antibody-dependent cellular cytotoxicity (ADCC) in macaques. J Virol 2013; 87: 13706-18.
158. Lloyd SB, Kent SJ, Winnall WR. The high cost of fidelity. AIDS Research and Human Retroviruses 2014; 30: 8-16.
157. Kent SJ. Towards Improved Influenza vaccines (editorial). Journal of Infectious Diseases 2014; 209: 4-5.
156. De Rose R, Fernandez CS, Hedger MP, Kent SJ, Winnall WR. Characterisation of macaque testicular leukocyte populations and T-lymphocyte immunity. J Reproductive Immunology 2013; 100: 146-156.
155. Wren L, Stratov I, Kent SJ, Parsons MS. Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. Vaccine 2013; 47: 5506-17.
154. Kramski M, Parsons MS, Stratov I, Kent SJ. HIV-specific antibody immunity mediated through NK cells and monocytes. Current HIV Research. 2013; 11: 388-406.
153. Munier CM, Kelleher AD, Kent SJ, De Rose R. The role of T cell immunity in HIV infection. Current Opinion in Virology 2013; 3: 438-46.
152. Yu X, Fernandez CS, Alcantara S, Bailey M, De Rose R, Kelleher AD, Zaunders J, Kent SJ. Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques. J Immunol Methods 2013; 394: 73-83.
151. Lim CK, Yap MMC, Kent SJ, Batten CJ, De Rose R, Heng B, Brew B, Guillemin GJ. Characterization of the Kynurenine Pathway and Quinolinic Acid Production in Simian Macrophages. International Journal of Tryptophan Res 2013; 6: 7-19.
150. Fernandez CS, Jegaskanda S, Godfrey DI, Kent SJ. In-vivo stimulation of macaque NKT cells with α-
Galactosylceramide. Clinical and Experimental Immunology 2013; 173: 480-92.
149. Cui J, De Rose R, Best JP, Johnston APR, Alcantara S, Liang K, Such GK, Kent SJ, Caruso F. Mechanically tunable, self-adjuvanting nanoengineered polypeptide particles. Advanced Materials 2013; 25: 3468-72.
148. Jegaskanda S, Laurie K, Amarasena T, Winnall WR, Kramski M, De Rose R, Barr IG, Brooks A, Reading PC, Kent SJ. Age-associated cross-reactive ADCC toward 2009-pandemic influenza. Journal of Infectious Diseases 2013; 208:1051-61.
147. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Antibody-dependent cellular cytotoxicity (ADCC) antibodies associated with control of pandemic H1N1 influenza infection of macaques. J Virol 2013; 87: 5512-22.
146. Kent SJ, Reece JC, Petravic J, Martyushev A, Kramski M, De Rose R, Cooper DA, Kelleher AD, Emery S, Cameron PU, Lewin SR, Davenport MP. The search for an HIV cure. Lancet ID 2013; 13: 614-21.
145. Major LD, Partridge TS, Gardner J, Kent SJ, De Rose R, Suhrbier A, Schroder WA. Induction of SerpinB2 and Th1/Th2 modulation by SerpinB2 during lentiviral infections in vivo. Plos One 2013; 8: e57343.
144. Reece JC, Alcantara S, Gooneratne S, Amarasena T, Fernandez CS, Laurie K, Hurt A, O'Connor S, Harris M, Petravic J, Martyushev A, Grimm A, Davenport MP, Stambas J, De Rose R, Kent SJ. Trivalent live attenuated Influenza-SIV vaccines: efficacy and evolution of CTL escape in macaques. J Virol 2013; 87: 4146-60.
143. Xu Y, Weatherall C, Bailey M, Alcantara S, De Rose R, Estaquier J, Wilson K, Suzuki K, Corbeil J, Cooper DA, Kent SJ, Kelleher AD, Zaunders J. SIV Infects Follicular Helper CD4 T cells in Lymphoid Tissues During Pathogenic Infection of Pigtail Macaques. J Virol 2013; 87: 3760-3773.
142. Madhavi V, Navis M, Chung AW, Isitman G, Wren LH, De Rose R, Kent SJ, Stratov I. Activation of NK cells by HIV-specific ADCC antibodies - role for granulocytes in presenting peptide epitopes. Human Vaccines and Immunotherapeutics 2013; 9: 1-9.
141. Parsons MS, Center RJ, Routy J-P, Rouleau D, LeBLanc R, Wainberg MA, Tremblay CL, Kent SJ, Bernard NF. Antibody responses to HIV Envelope from infections with multiple viral types and subtypes utilize the 1F7-idiotypic repertoire. AIDS Res Human Retro 2013; 29: 778-793.
140. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, De Rose R, Winnall WR, Stratov I, Brooks A, Reading PC, Kent SJ. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity (ADCC) antibodies in the absence of neutralizing antibodies. J Immunol 2013; 190: 1837-1848.
139. French MA, Center RJ, Wilson KM, Fleyfel I, Fernandez S, Schorcht A, Stratov I, Kramski M,Kent SJ, Kelleher AD . Isotype switched IgG antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' HLA-B alleles in HIV controllers. AIDS 2013; 27: 519-528.
138. Stratov I, Denholm J, Kent SJ. Azithromycin – more lethal than chloramphenicol? Sexual Health 2013; 10: 179-82.
137. Wren L, Chung A, Isitman G, Kelleher AD, Parsons MS, Amin J, Cooper DA, Stratov I, Navis M, Kent SJ. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013; 138: 116-123
136. Madhavi V, Kent SJ, Stratov I.HIV-specific Antibody-Dependent Cellular Cytotoxicity: a Novel Vaccine Modality. Expert Review of Clinical Immunology 2012; 8: 767-74.
135. Kramski M, Schorcht A, Johnston APR, Lichtfuss G, De Rose R, Jegaskanda S, Stratov I, Kelleher AD, French MA, Center RJ, Jaworowski A, Kent SJ. Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J Imm Methods 2012; 384: 51-61.
134. Fernandez CS, Cameron G, Godfrey I, Kent SJ. Ex-vivo alpha-Galactosylceramide activation of NKT cells in humans and macaques. J Imm Methods 2012; 382: 150-159.
133. Kramski M, Lichtfuss GF, Navis M, Isitman G, Wren L, Rawlin G, Center RJ, Jaworowski A, Kent SJ, Purcell DF. Anti-HIV antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. Eur J Immunol 2012; 42: 2771-81.
132. Wren L, Parsons S, Isitman G, Center RJ, Kelleher AD, Stratov I, Bernard NF, Kent SJ. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. Plos One 2012; 7: e38580.
131. Winnall WR, Sexton A, Roath S, Alcantara S, De Rose R, Kent SJ. Characterisation of Simian Immunodeficiency Virus-infected cells in pigtail macaques. Virology 2012; 428: 11-20.
130. Jegaskanda S, Reece J, De Rose R, Stambas J, Sullivan L, Brooks AG, Kent SJ, Sexton A. Comparison of Influenza and SIV specific CD8 T cell responses in macaques. Plos One 2012; 7: e32431.
129. Kent SJ. Loss of control of HIV viremia associated with fat malabsorption drug orlistat. AIDS Res Human Retro 2012; 28: 961-2.
128. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, Heath WR, Carbone F, Gephardt T. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. PNAS 2012; 109: 7037-7042.
127. Isitman G, Stratov I, Kent SJ. Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Advances in Virology 2012; e637208.
126. Parsons M, Wren L, Isitman G, Navis M, Stratov I, Bernard N, Kent SJ. HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol 2012; 86: 4488-95.
125. Reece J, Petravic J, Balamurali M, Loh L, Gooneratne S, De Rose R, Kent SJ, Davenport MP. An ''Escape Clock'' for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells. Plos Pathogens 2012; 8: e1002615.
124. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, Kent SJ, Stratov I. Activation of NK cells by ADCC antibodies and HIV disease progression. J AIDS 2011; 58: 127–131.
123. Queen SE, Mears BM, Kelly KM, Dorsey JL, Liao Z, Dinoso JB, Gama L, Adams J, Zink MC, Clements JE, Kent SJ, and Mankowski JL. Replication competent SIV Gag escape mutations archived in latent reservoirs during anti-retroviral treatment of SIV-infected macaques. J Virol 2011; 85: 9167-9175.
122. Pitisuttithum P, Rerks-Ngarm S, Chiu J, Kim J, Benenson M, Kent SJ, Tamashiro H, Marique A, Bernstein A, Goyal R, Ditangco RA, Cooper DA, Osmanov S, Mathieson B, Sandstrom E, Esparza J, Hoff R, Shao Y. Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan). Southeast Asian J Trop Med Public Health 2011; 42: 1130-46.
121. Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, Hinkula J, Wahren B, Kärre K, Kent SJ, Berg L. NK cell function and antibodies mediating ADCC in HIV-1 infected viremic and controller patients. Viral Immunology 2011; 24: 359-368.
120. Chung AW, Isitman G, Navis M, Kramski M, Center RC, Kent SJ, Stratov I. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. PNAS 2011; 108: 7505–10.
119. Fernandez CS, Reece JC, Saepuloh U, De Rose R, Ishkandriati D, O'Connor DH, Wiseman RW, Kent SJ. Screening and confirmatory testing of MHC class I alleles in pigtail macaques. Immunogenetics 2011; 63: 511-21.
118. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011; 412: 110-6.
117. Chung AW, Navis M, Isitman G, Center R, Finlayson R, Bloch M, Gelgor L, Kelleher AD,Kent SJ, Stratov I. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunology 2011; 24: 171-5.
116. Wren L, Kent SJ. HIV Vaccine efficacy trials - glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Human Vaccines 2011; 7: 466-73.
115. Reece JR, Loh L, Alcantara S, Fernandez CS, Stambas J, Sexton A, De Rose R, Petravic J, Davenport MP, Kent SJ. Timing of immune escape linked to success or failure of vaccination. Plos One 2010; 5: e12774
114. Kent SJ, Cooper DA, Vun MC, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Kink NV, Bernstein A, Osmanov S. AIDS Vaccine for Asia Network (AVAN): Expanding the regional role in developing HIV vaccine. Plos Medicine 2010; 7: e1000331
113. Balamurali B, Petravic J, Loh L, Alcantara S, Kent SJ, Davenport MP. Does cytolysis by CD8+ T cells drive immune escape in SHIV infection? J Immunol 2010; 185: 5093-5101. (Highlighted by the editors in "In this issue").
112. Rerks-Ngarm S, Pitisuttithum P, Ganguly N, Zhang L, Tamashiro H, Cooper DA, Mean Chhi Vung, Bela B, Ditangco R, Nguyen Van Kinh, Bernstein A, Osmanov S, Mathieson B, Kent SJ, Shao Y. Defining the objectives of the AIDS vaccine for Asia network. Current Opinion in HIV/AIDS 2010; 5: 435-452
111. Isitman G, Navis M, Kent SJ, Stratov I. Designing immunity to HIV: Manipulating antibody-dependent cellular cytotoxicity antibodies. Future Medicine 2009; 3: 633-640.
110. Sexton A, Whitney PG, Chong SF, Zelikin AN, Johnston APR, De Rose R, Brooks AG, Caruso F, Kent SJ. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 2009; 3: 3391-3400.
109. Center RJ, Wheatley AK, Campbell SM, Gaeguta AJ, Peut V, Alcantara S, Siebentritt C, Kent SJ, Purcell DFJ. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 2009; 27: 6605-6612.
108. Chong SF, Sexton A, De Rose R, Kent SJ, Zelikin AN, Caruso F. A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials 2009; 30: 5178-5186.
107. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M, Xu Y, Brown K, Dyer WB, Kim M, de Rose R, Kent SJ, Jiang L, Breit SN, Emery S, Cunningham AL, Cooper DA, Kelleher AD. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated co-expression of CD25 and CD134 (OX40). J Immunol 2009; 183: 2827-2836
106. Peut V, Campbell S, Gaeguta A, Center RJ, Wilson K, Alcantara S, Fernandez CS, Purcell DFJ, Kent SJ. Balancing reversion of CTL and neutralizing antibody escape mutations within HIV-1 Env upon transmission. J Virol 2009; 83: 8986-8992.
105. Chang J, Sitrivichayakul S, Avihingsanon A, Thompson AJV, Revill P, Iser D, Slavin J, Buranapraditkun S, Marks P, Matthews G, Cooper DA, Kent SJ, Cameron PU, Sasadeusz J, Desmond P, Locarnini S, Dore GJ, Ruxrungtham K, Lewin SR. Impaired qualityof the HBV-specific T cell response in HIV-1 HBV co-infection. J Viro 2009; 83: 7649-7658.
104. Sexton A, De Rose R, Reece JC, Alcantara S, Loh L, Moffat JM, Laurie K, Hurt A, Doherty PC, Turner SJ,Kent SJ, Stambas J. Evaluation of recombinant Influenza-SIV vaccines in macaques. J Virol 2009; 83: 7619-7628.
103. Alcantara S, Reece JC, Amarasena T, De Rose R, Manitta J, Amin J, Kent SJ. Thrombocytopenia is strongly associated with simian AIDS in pigtail macaques. J AIDS 2009; 51: 374-379.
102. Mason RD, De Rose R, Kent SJ. Differential patterns of immune escape at Tat-specific cytotoxic T cell epitopes in pigtail macaques. Virology 2009; 388: 315-323.
101. Loh L, Reece JC, Fernandez CS, Alcantara S, Center R, Howard J, Purcell DFJ, Balamurali M, Petravic J, Davenport MP,Kent SJ. Complexity of the inoculum determines the rate of reversion of SIV Gag CD8 T cell mutant virus and outcome of infection.PloS Pathogens 2009; 5(4): e1000378.
100. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI,Kent SJ. Peripheral NKT cells in SIV-infected macaques. Journal of Virology 2009; 83: 1617-1624.
99. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. Journal of Immunology 2009; 182: 1202-1210.
98. Peut V, Kent SJ. Substantial Envelope-specific CD8 T cell immunity fails to control SIV. Virology 2009; 384: 21-27.
97. Mason RD, Alcantara S, Peut V, Loh L, Lifson JD, De Rose R, Kent SJ. Inactivated SIV-pulsed autologous fresh blood cells as an immunotherapy strategy. Journal of Virology 2009; 83: 1501-1510.
96. De Rose R, Mason RD, Loh L, Peut V, Smith MZ, Fernandez CS, Alcantara S, Amarasena T, Reece J, Seddiki N, Kelleher AD, Zaunders J, Kent SJ. Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques. Journal of Medical Primatology 2008; 37 (Supp 2): 69-78.
95. Mankowski JL, Queen SE, Fernandez CS, Tarwater PM, Karper JM, Adams RJ, Kent SJ. Natural Host Genetic Resistance to Lentiviral CNS disease: A Neuroprotective MHC Class I Allele to SIV-infected Macaques. PloS ONE 2008; 3(11): e3603. doi:10.1371/journal.pone.0003603.
94. De Rose R, Zelikin A, Johnston APR, Sexton A, Chong SF, Cortez C, Mulholland W, Caruso F, Kent SJ. Binding, Internalisation and Antigen Presentation of Vaccine-Loaded Nanoengineered Capsules in Blood. Advanced Materials 2008; 20: 4698-4703.
93. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I. The Utility of ADCC responses in HIV infection. Current HIV Research 2008; 6: 515-519.
92. Davenport MP, Loh L, Petravic J, Kent SJ. Rates of HIV immune escape and reversion in HIV: Implications for viral evolution and vaccination. Trends in Microbiology 2008; 16: 561-566.
91. Mason RD, De Rose R, Seddiki N, Kelleher AD, Kent SJ. Low pre-infection levels and loss of central memory CD4+ T cells may predict rapid progression in SIV-infected pigtail macaques. Virology 2008; 381: 11-15.
90. Rollman E, Mason RD, Lin J, Brooks AG, Kent SJ. Protection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs. Journal of Medical Primatology 2008; 37 (Supp 2): 24-32.
89. De Rose R, Fernandez CS, Loh L, Peut V, Mason RD, Alcantara S, Reece J, Kent SJ. Delivery of immunotherapy with peptide-pulsed blood in macaques. Virology 2008; 378: 201-204.
88. Smith MZ, Asher TE, Venturi V, Davenport MP, Douek DC, Price DA, Kent SJ. Limited maintenance of vaccine-induced SIV-specific CD8 T cell receptor clonotypes after virus challenge. J Virol 2008; 82: 7357-7368.
87. De Rose R, Fernandez CS, Smith MZ, Batten CJ, Alcantara S, Peut V, Rollman E, Loh L, Mason RD, Wilson K, Law MG, Handley AJ, Kent SJ. Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood. PloS Pathogens 2008; 4(5): e1000055. doi:10.1371/journal.ppat.1000055.
86. Rollman E, Turner SJ, Kedzierska K, Kent SJ. Anti-SIV cytolytic molecules in pigtail macaques. AIDS Research and Human Retroviruses 2008; 24: 1127-1131.
85. Loh L, Kent SJ. Quantification of Simian Immunodeficiency Virus Cytotoxic T Lymhocyte Escape Mutant Viruses. AIDS Research and Human Retroviruses 2008; 24: 1067-1072.
84. Stratov I, Chung A, Kent SJ. Robust NK-cell mediated HIV-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82: 5450-5459.
83. Mason RD, De Rose R, Kent SJ. CD4+ T cell subsets: what really counts in preventing HIV disease? Expert Review of Vaccines 2008; 7: 155-158.
82. Petravic J , Loh L, Kent SJ, Davenport MP. CD4+ Target cell availability determines the dynamics of immune escape and reversion in vivo. J Virol 2008; 82: 4091-4101.
81. Kent SJ, De Rose R, Mokhonov VV, Mokhonova EI, Fernandez CS, Alcantara S, Rollman E, Mason RD, Loh L, Peut V, Reece JC, Wang XJ, Wilson KM, Suhrbier A, Khromykh A. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques. Virology 2008; 374: 528-534.
80. Woollard DJ, Haqshenas G, Dong X, Pratt BF, Kent SJ, Gowans EJ. Virus-Specific T-Cell Immunity Correlates with Control of GB Virus Type B Infection in Marmosets. J Virol 2008; 82: 3054-3060.
79. Loh L, Petravic J, Batten CJ, Davenport MP, Kent SJ. Vaccination and timing influence SIV immune escape viral dynamics in vivo. PloS Pathogens 2008; 4(1): e12 doi:10.1371/journal.ppat.0040012.
78. Chang JJ, Thompson A, Visvanathan K, Kent SJ, Cameron PU, Wightman F, Bowden S, Desmond P, Locarnini SA, Lewin SR. Th1/Th2 imbalance of Hepatitis B Virus (HBV)-specific T-cells in the liver of chronic HBV patients associated with liver damage without viral clearance. Hepatology 2007; 46: 1332-1340.
77. Peut V, Kent SJ. Utility of HIV-1 Envelope as a T Cell Immunogen. J Virol 2007; 81: 13125-13134.
76. Rollman E, Smith MZ, Brooks A, Purcell DFJ, Zuber B, Ramshaw IA, Kent SJ. Killing kinetics of SIV-specific CD8+ T cells: implications for HIV vaccine strategies. Journal of Immunology 2007; 179: 4571-4579.
75. Fernandez C , Smith M, Batten C, De Rose R, Reece J, Rollman E, Venturi V, Davenport M, Kent SJ. Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol 2007; 81: 4137-4144.
74. Shehu-Xhilaga M, Kent SJ, Batten CJ, Ellis S, Van der Meulen J, O'Bryan M, Cameron PU, Lewin SR, Hedger MP. The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. Retrovirology 2007; 4:7.
73. Kent SJ, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Current Opinion in Investigational Drugs 2007; 8:159-167.
72. Loh L, Batten CJ, Petravic J, Davenport MP, Kent SJ. In vivo fitness costs of different Gag CD8 T cell escape mutant simian-human immunodeficiency viruses in macaques. J Virol 2007; 81: 5418-22. View supplementary tables .
71. De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Venturi V, Davenport MP, Kent SJ. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 2007; 81: 292-300.
70. Pratt BF, O'Connor DH, Lafont BAP, Mankowski JL, Fernandez CS, Triastuti R, Brooks AG, Kent SJ, Smith MZ. MHC class I allele frequencies in pigtail macaques of diverse origin. Immunogenetics 2006; 58: 995-1001.
69. De Rose, R, Sullivan MT, Dale CJ, Kelleher AD, Emery, S, Cooper DA, Ramshaw IA, Boyle DB, Kent SJ. Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines. Human Vaccines 2006; 2: 134-136.
68. Zaunders J, Dyer WB, Munier ML, Ip S, Liu J, Amyes E, Rawlinson B, De Rose R, Kent SJ, Sullivan JS, Cooper DA, Kelleher AD. D127+ CCR5+ CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia and precede IL-2+ memory CD4+ T cells. J Virol 2006; 80: 10151-10161.
67. Kelleher A, Puls R, Bebbington M, Boyle DB, Ffrench RA, Kent SJ, Law MG, Purcell DFJ, Ramshaw IA, Cooper DA, Emery S. A randomised, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20: 294-297.
66. Stratov I, Dale CJ Chea S, Montefiori DC, De Rose R, Reece JC,Kent SJ. Characteristics of effective immune control of Simian/Human Immunodeficiency Virus in pigtail macaques. AIDS Research and Human Retroviruses 2006; 22: 27-32.
65. Batten CJ, De Rose R, Wilson KM, Agy MB, Chea S, Stratov I, Montefiori DC, Kent SJ. Comparative evaluation of simian, simian-human, and human Immunodeficiency virus infection in the pigtail macaque (Macaca nemestrina) model. AIDS Research and Human Retroviruses 2006; 22: 580-588.
64. Peut V, Kent SJ. Fitness constraints on immune escape from HIV: Implications of Envelope as a target for both HIV-specific T cells and antibody. Current HIV Research 2006; 4: 191-7.
63. Coupar BE, Purcell DF, Thomson SA, Ramshaw IA,Kent SJ, Boyle DB. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 2006; 24: 1378-88.
62. Smith MZ, Fernandez CS, Chung A, Dale CJ, De Rose R, Lin J, Brooks AG, Krebs KC, Watkins DI, O'Connor DH, Davenport MP, Kent SJ. The pigtail macaque MHC class I allele Mane-A*10 presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. J Med Primatol 2005; 34: 282-93.
61. Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BEH, Boyle DB, Law M, Wilson KM, Ramsay AJ. Mucosally-administered Human-Simian Immunodeficiency Virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005; 23: 5009-21.
60. Thomson SA, Jaramillo AB, Shoobridge M, Dunstan KJ, Everett B, Ranasinghe C, Kent SJ, Medveckzy C, Ffrench RA, Ramshaw IA. Development of a Synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 2005; 23: 4647-57.
59. Kent SJ, Fernandez CS, Dale CJ, Davenport MP. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. Trends in Microbiology 2005; 13: 243-6.
58. Stratov I, Dale CJ, Chea S, McCluskey J, Kent SJ. Induction of T-cell immunity to antiretroviral drug-resistant HIV-1. Journal of Virology 2005; 79: 7728-39.
57. Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, Smith MZ, Agy MB, Hu S-L, Krebs K, Watkins DI, O'Connor DH, Davenport MP, Kent SJ. Rapid viral escape at an immunodominant SHIV CTL epitope exacts a dramatic fitness cost. Journal of Virology 2005; 79: 5721-31.
56. Stratov I, Dale CJ, Kent SJ. Phenotypic and kinetic analysis of effective Simian-Human Immunodeficiency Virus-specific T-cell responses in DNA and Fowlpoxvirus vaccinated macaques. Virology 2005; 337: 222-234.
55. De Rose R, Taylor EL, Law M, Van der Meide PH, Kent SJ. Granulocyte contamination dramatically inhibits spot formation in AIDS virus-specific ELISpot assays: analysis and strategies to ameliorate. Journal of Immunological Methods 2005; 279: 177-86.
54. Pamungkas J, De Rose R, Iskandriati D, Noviana R, Paramastri Y, Dale CJ, Shoobridge M, Medveczky CJ, Ramshaw IA, Thomson SA, Kent SJ. Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and Fowlpoxvirus boost HIV-1 vaccine regimens in macaques. AIDS Research and Human Retroviruses 2005; 21: 292-300.
53. Dale CJ, Thomson S, De Rose R, Ranasinghe C, Medveczky CJ, Pamungkas J, Boyle DB, Ramshaw IA, Kent SJ. Prime boost strategies in DNA Vaccines. In: DNA Vaccines , 2nd edition Ed: M Salzman; Humana Press 2006: 171-198.
52. Chang JJ, Wightman F, Bartholomeusz A, Ayres A, Kent SJ, Sasadeusz J, Lewin SR. Reduced HBV-specific T-cell responses in HIV-1-HBV co-infected individuals receiving HBV-active antiretroviral therapy. Journal of Virology 2005; 79: 3038-51.
51. Chea S, Dale CJ, De Rose R, Ramshaw IA, Kent SJ. Enhanced cellular immunity in macaques following a novel peptide immunotherapy. Journal of Virology 2005: 79; 3748-3757.
50. Smith MZ, Kent SJ. Genetic influences on HIV infection: implications for vaccine development. Sexual Health 2005: 2; 53-62.
49. De Rose R, Chea S, Dale CJ, Reece J, Fernandez CS, Wilson KM, Thomson S, Ramshaw IA, Coupar BEH, Boyle DB, Sullivan MT, Kent SJ. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding 5 shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 2005: 23; 1949-1956.
48. Dale CJ, De Rose R, Stratov I, Chea S, Montefiori D, Thomson S, Ramshaw IA, Coupar BEH, Boyle DB, Law M, Kent SJ. Efficacy of DNA and Fowlpoxvirus prime/boost vaccines for SHIV. Journal of Virology 2004; 78: 13819-13828.
47. Smith MZ, Dale CJ, De Rose R, Stratov I, Fernandez CS, Brooks AG, Weinfurter J, Krebs K, Riek C, Watkins DI, O'Connor DH, Kent SJ. Analysis of Pigtail Macaque Major Histocompatibility Complex Class I Molecules Presenting Immunodominant Simian Immunodeficiency Virus Epitopes. Journal of Virology 2005; 79: 684-695.
46. Dale CJ, De Rose R, Wilson KM, Croom HA, Thomson S, Coupar BEH, Ramsay A, Purcell DFJ, Ffrench R, Law M, Emery S, Cooper DA, Ramshaw IA, Boyle DB, Kent SJ. Evaluation of HIV-1 DNA vaccines optimized for primate CpG content and fowlpoxvirus vaccines co-expressing IFNg or IL-12. Vaccine 2004; 23: 188-197.
45. Stratov I, DeRose R, Purcell DFJ, Kent SJ. Vaccines and vaccine strategies against HIV. Current Drug Targets, 2004; 5: 71-88.
44. Thompson KA, Kent SJ, Gahan ME, Purcell DFJ, McLean CA, Preiss S, Dale CJ, Wesselingh SL. Neurotropism of nef/LTR deleted Simian Immunodeficiency Virus. J Neurovirol 2003; 9: 442-451.
43. Dale CJ, Liu XS, De Rose R, Purcell DFJ, Anderson J, Xu Y, Leggatt GR, Frazer IH, Kent SJ. Chimeric human papilloma virus – simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology 2002; 301: 176-87.
42. Corbett AJ, McKenzie BS, Sutherland RM, Brady JL, Strugnell RA,Kent SJ, Kramer DR, Boyle JS, Pearse MJ and Lew, AM (2002) The utility of immunoglobulin fusions in DNA vaccines In: The Antibodies, Vol 7 pp29-42. Ed M Zanetti & JD Capra, Taylor & Francis, London.
41. Kent SJ, Dale CJ, Mijch AM. Knowledge and commitment for action. The 14th International AIDS Conference, Barcelona, July 2002. Medical Journal of Australia 2002; 177: 587-9.
40. Kent SJ. Vaccines for HIV in the developing world. Internal Medicine Journal 2002; 32: 136-7.
39. Kent SJ, Dale CJ, Preiss S, Purcell DFJ. Evidence of recombination between 3' and 5' LTRs in macaques inoculated with SIV DNA. AIDS Research and Human Retroviruses 2002; 18: 227-30.
38. Kent SJ, Dale CJ, Preiss S, Mills J, Campagna D, Purcell DFJ. Vaccination with attenuated simian immunodeficiency virus by DNA inoculation. J Virol 2001; 75: 11930-4.
37. Kent SJ, Ada GL, Hayes E, Lewis IM. Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques. Immunological Reviews 2001; 183: 94-108.
36. McKenzie BS, Corbett AJ, Brady JL, Dyer CM, Strugnell RA,Kent SJ, Kramer DR, Boyle JS, Lew AM. Enhancing nucleic acid vaccines: task and tactics. Immunologic research 2001; 24: 225-44.
35. Kent SJ, Cameron PU, Reece J, Thompson P, Purcell DFJ. Attenuated and wild type HIV-1 infections and Long Terminal Repeat mediated gene expression from plasmids delivered by gene gun to human skin ex vivo and macaques in vivo. Virology 2001; 287: 71-8.
34. Purcell DFJ, Cameron PU, Mills J,Kent SJ. Infectivity of wild-type and deleted proviral SIV DNA. Developments in Biologicals 2001; 106: 395-406.
33. Joy AK, Vogelnest L, Middleton DJ, Dale CJ, Campagna D, Purcell DFJ, Kent SJ. SIV infections in vervet monkeys (Clorocebus aethiops) at an Australian zoo. Aust Veterinary Journal 2001; 79: 406-8.
32. Kent SJ. Vaccines to prevent HIV and AIDS. Microbiology Australia 2001; 22: 12-15.
31. Sands AR, Kent SJ, Dax EM, Johnson EM. Antibody responses to an HIV-1 vaccine. Proceedings of the 6th European Conference on Experimental AIDS Research. Monduzzi Ed, Bologna, Italy, 2001: 75-80.
30. Kent SJ, Zhao A, Dale CJ, Land S, Boyle DB, Ramshaw IA. A recombinant avipox HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 2000; 18: 2250-6.
29. Dale CJ, Zhao A, Jones SL, Boyle DB, Ramshaw IA, Kent SJ. Induction of T-helper type 1 responses following therapeutic vaccination of macaques with a recombinant fowlpoxvirus HIV-1 vaccine co-expressing interferon-gamma. J Med Primatol 2000; 29: 240-7.
28. Dale CJ, Kent SJ. Vaccines for HIV. Expert Opinion on Therapeutic patents 2000; 10: 1179-88.
27. Ramsay AJ, Kent SJ, Strugnell RA, Suhrbier A, Thomson SA, Ramshaw IA. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunological Reviews 1999; 171: 27-44.
26. Kent SJ. HIV vaccines – promise and directions. Medical Journal of Australia 1999; 171: 124-5.
25. Kent SJ. Vaccination for HIV infected individuals. Position paper of the Australasian Society for HIV medicine, 1999.
24. Kent SJ, Zhao A, Best S, Chandler JD, Boyle D, Ramshaw IA. Enhanced T cell immunogenicity and protective efficacy of a HIV-1 vaccine regimen consisting of consecutive DNA priming and recombinant fowlpox virus boosting. Journal of Virology 1998; 72: 10180-8.
23. Joy AK, Dale CJ, Kent SJ. Can HIV be prevented by a vaccine? Drugs R & D 1999; 1: 431-40.
22. Kent SJ, Lewis IM. Primate Syngeneic modelling systems for HIV vaccines. Reproduction Fertil Dev 1998; 10: 651-7.
21. Kent SJ. Preventive HIV-1 vaccines: Where are we going? Int. J. of STD and AIDS 1998; 9: 715-9.
20. Kent SJ. Antiviral CD4 cell response in simian immunodeficiency virus infected macaques. Journal of Infectious Diseases 1998; 177: 1771-2.
19. Cardinal B, Kent SJ. Behavioural effects of simple manipulable environmental enrichment techniques on macaques. Laboratory Primate Newsletter 1998; 37: 1-4.
18. Looney DJ, MacClure J, Kent SJ, Radaelli A, Kraus G, Schmidt A, Steffy K, Greenberg P, Hu S-L, Morton W, Wong-Staal F. A minimally replicative HIV-2 live-virus vaccine protects M nemestrina from disease after HIV-2287 challenge. Virology 1998; 242: 150-60.
17. Kent SJ, Woodward A, Zhao A. HIV-1 specific T cell responses correlate with control of acute HIV-1 infection in macaques. Journal of Infectious Diseases 1997; 176: 1188-97.
16. Mills J, Deacon N, McPhee D, Learmont J, Crowe SM, Greenway A, Rhodes D, Oelrichs R, Kent SJ, Geczy A, Sullivan J. Effects of 13-17 years of infection with a nef-deleted strain of HIV: the Sydney Blood Bank Cohort. in: Colloque Des Cent Gardes: Retroviruses of Human AIDS and Related Animal Diseases. Eds Girard M and Dodet B. 1997 p293-9.
15. Kent SJ, Greenberg PD, Hoffman MC, Akridge R, McElrath MJ. Antagonism of vaccine-induced CD4+ CTL by primary HIV-1 infection: potential mechanism of vaccine failure. Journal of Immunology 1997; 158: 807-15.
14. Dyer WB, Geczy AF, Kent SJ, McIntyre LB, Blasdall SA, Learmont JC, Sullivan JS. Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. AIDS, 1997; 11: 1565-74.
13. Kent SJ, Hu S-L, Corey L, Morton WR, Greenberg PD. Detection of SIV-specific CD8+ T cells in Macaques protected from SIV challenge by prior subunit vaccination. Journal of Virology 1996; 70: 4941-9.
12. Kent SJ, Clancy R, Ada GL. Prospects for a preventative HIV vaccine. Medical Journal of Australia, 1996; 165: 212-5.
11. Kent SJ, Corey L, Agy M, Morton WR, McElrath MJ, Greenberg PD. Cytotoxic and proliferative T cell responses in HIV-1 infected M nemestrina. Journal of Clinical Investigation 1995; 95: 248-56.
10. Biggs BA, Hewish M,Kent SJ, Hayes K, Crowe SM. HIV infection of human monocyte derived macrophages impairs ingestion and killing of Toxoplasma gondii. Journal of Immunology 1995; 154: 6132-9.
9. Kent SJ, Stallard V, Corey L, Hu S-L, Morton WR, Gritz L, Panacali D, Greenberg PD. Analysis of SIV-specific CTL responses in SIV infected macaques using antigen specific stimulations with recombinant vaccinia and fowlpox viruses. AIDS Research and Human Retroviruses 1994; 5: 551-60.
8. Kent SJ, Stent G, Sonza S, Hunter SD, Crowe SM. HIV-1 Infection of Monocyte-derived Macrophages Reduces Fc and Complement Receptor Expression. Clinical and Experimental Immunology 1994; 95: 450-4.
7. Crowe SM, Vardaxis N,Kent SJ, Maerz A, Hewish MJ, McGrath MS, Mills J. HIV-1 infection of monocyte-derived macrophages in vitro reduces phagocytosis of Candida albicans. Journal of Leukocyte Biology 1994; 56: 318-27.
6. Swanson CE, Tindall B, Cooper DA for the Australian Zidovudine Study Group* (Kent SJ, member of study group) Efficacy of zidovudine treatment in homosexual men with ARC. AIDS 1994; 8: 625-34.
5. Kent SJ, Van Scoy MS, Skerrett S. Listeria peritonitis with review of the literature. Aust N Z J Med 1994; 24: 405.
4. Kent SJ, Crowe SM, Yung A, Lucas CR, Mijch AM. Tuberculous meningitis - A 30 year review. Clinical Infectious Diseases 1993; 17: 987-94.
3. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992; 6: 1169-74.
2. Kent SJ, Hoy JF. Prevention of Meningoccal infections. Current Therapeutics 1992; 33: 43-46.
1. Fairley CK ,Kent SJ, Street A, Mijch A, Hoy JF. Invasive aspergillosis in AIDS. Aust N Z J Med 1991; 21: 747-9.
Research Staff
Post Doctoral Fellows
Dr Amy Chung
Dr Amy Chung completed her PhD with our group in 2011 and was then awarded both an NHMRC CJ Martin award and an Australia-America fellowship to work with Dr Galit Alter at Harvard University/Ragon Institute. She had a highly successful post-doc there with first authored publications in Science Translational Medicine and cell. She returns on the Australian leg of her NHMRC CJ Martin fellowship to set up projects on novel aspects of antibody immunity. She is studying aspects of "Systems Serology" (see Chung et al, Cell 2015) whereby a complete picture of functional antibody responses is analysed to HIV, TB and other pathogens. She has developed novel multiplex assays to generate this broad picture of antibody immunity. She is supervising a PhD student, Matthew Worley, and a Research Assistant. She has received University of Melbourne Early Career grants and a D'Esterre-Taylor Charitable Trust grant to continue her work.
Dr Adam Wheatley
Dr Adam Wheatley completed his PhD in this department in 2010. He then worked as a post-doctoral scientist at the NIH's Vaccine Research Centre in the US with Drs Rick Koup, Adrian McDermott and others. He is now both helping to develop novel nano-medicine projects and is developing insight into B cell and antibody based immunity projects to influenza and HIV. In particular, he is pioneering haemagluttin fluorescent probes to study Influenza B cell biology and drive improvements in Influenza vaccines. Some of his work on this topic was published in Cell this year (Cell 2016; 166: 609-623). He is supervising PhD students, Yi Liu and Hannah Kelly. He has received an Early Career Research Grant from the University of Melbourne and he is a co-investigator on our 2016 ACH2 Award.
Dr Matt Parsons
Dr Matt Parsons completed his PhD at McGill in Canada in 2012 and joined us in Nov 2012. He is an expert in NK cell biology and HIV. He spent 6 months with us during his PhD, which was very stimulating and highly productive. He is studying subtypes of NK cells for their ability to mediate HIV-specific ADCC responses. He is also interested in how ADCC antibodies could help prevent infection with cell-associated HIV. Together with Prof. Kent, he was awarded ACH2 grants in 2014 and 2016, as well as an NHMRC Project Grant in 2015 to continue his work. He has been awarded Canadian Institutes of Health Research and Doherty Fellowships. He is supervising PhD students Wen Shi Lee and Kevin John Selva and Research Assistant Anne Kristensen.
Vijaya Madhavi
Vijaya started a PhD with us in 2012. She is studying how HIV-specific ADCC epitopes are presented to the immune system with a view to improving the generation of immunity by HIV vaccines. She obtained her Masters in Microbiology from the University of Hyderabad in India where she topped her class. She is making great progress in investigating the presentation of ADCC epitopes, the role of antiretroviral therapy on ADCC immunity, and the breadth of ADCC recognition of HIV strains. She is also working on collaborative ADCC immunity projects with the National AIDS Research Institute in India. She will be taking up a post-doctoral position with Prof Jamie Rossjohn at Monash in January 2017.
Jennifer Juno
Jennifer is a talented Canadian postdoctoral fellow who started with us in September 2016. She completed a PhD at the University of Manitoba in 2014 on aspects of HIV disease progression. She has recently been working at the National Laboratory for HIV Immunology – HIV/TB Co-infection Unit at the Public Health Agency of Canada in Winnipeg. She joins us with an interest in HIV/SIV, TB, MAIT cells, gamma-delta cells and CD1-restricted T cells. She has been awarded Canadian Institutes of Health Research and NHMRC Early Career fellowships.
Hyon-Xhi Tan
Hyon Xhi graduated with a BSc (Hons) from the University of Otago NZ in 2010 where he won several prestigious awards. He hails from Malaysia originally. He started his PhD in 2013 and has developed a series of Influenza-HIV vaccines and studied their ability to induce resident memory T cells. He has developed a number of innovative in situ based staining techniques to study tissue-based immunity. He submitted his PhD thesis in August 2016 and is working with us finishing off some exciting work from his PhD. He is working with Adam to develop an understanding of influenza-specific B cell responses in tissues.
Research Assistants
Vinca Alcantara
Vinca completed her Bachelor of Science (Clinical Laboratory Science) at Silliman University in the Philippines in 1994. She joined the Kent Lab in 2005 and works as a Research Technician. She is highly expert at flow cytometry including tetramer staining on T cells. She makes everyone's life easier by coordinating general lab management and maintenance. She is working on various collaborative nano-particle projects and on the "Advice" clinical trial of a PAR-1 inhibitor in HIV infection.
Thakshila Amarasena
Thakshila is an experienced technical scientist helping with our studies of viral quantification, sequencing and flow cytometry. She obtained her science degree in Sri Lanka and is a very experienced laboratory scientist. She is also our diligent safety and compliance officer.
Anne Kristensen
Anne completed the research component of her MSc from the University of Copenhagen in Denmark with us here in Melbourne and received top marks! She has now returned to our group as an expert research assistant working with Dr Matt Parsons on a series of HIV ADCC projects. She is well versed on a wide range of ADCC and NK cell assays.
Megan Schepers
Megan took over coordinating our animal facility in Geelong in 2011 but has worked with us part time for many years prior to that. She is doing a wonderful job caring for our animals and coordinating our five other part time staff members. Megan trained at Deakin both as a BSc science graduate and a registered nurse. In between all her hard work she has given birth to two lovely children!
Sriveni Pantham
Sriveni is working with us part time as a research assistant helping Vinca and Thakshila manage the lab so capably. Sriveni graduated with a MSc in Microbiology from Acharya Nagarjuna University in India and has experience working for a number of biotechnology companies.
Sarah Lloyd
Sarah is a University of Melbourne BSc (Hons) graduate, who completed her Honours year with Wendy Winnall in our lab in 2012. She constructed HIV/SIV viruses that mutate more slowly to understand how HIV/SIV evolves and causes disease. She has looked at the role and costs of reverse transcriptase fidelity, and also contributed to a series of antibody-based HIV/SIV immunity projects. She submitted her PhD thesis in August 2016.
Fernanda Ana-Sosa Batiz
Fernanda graduated with a BSc from Universidad Autónoma de Baja California in Mexico in 2008. She is doing her PhD on antibody-dependent phagocytosis immunity to HIV and Influenza.
Kevin John Selva
Kevin completed his BSc (Hons) at the Nanyang Technical University in Singapore and has subsequently worked as a research assistant on NK cell immunity to adenovirus infections in the eye. He joined our group to conduct a PhD on aspects of NK cell biology and ADCC immunity to HIV with Dr Matt Parsons. He is studying how factors within seminal plasma cause immune-suppression, inhibiting the ability of NK cells to mediate ADCC and enhance HIV transmission.
Wen Shi Lee
Wen Shi completed a Bachelor of Biomedicine at the University of Melbourne in 2013 and completed First Class Honours with us in 2014. His PhD studies focus on understanding how to clear latently infected cells and cure HIV using ADCC antibodies. Wen Shi has broad skills in both ADCC immunity and HIV virology. He is also studying how viral rebound during cure therapies or treatment interruption boosts ADCC.
Hilary Vanderven
Hillary completed her MSc at the University of Alberta in Canada in 2011 and worked as a research assistant, laboratory coordinator and lecturer after that. She moved to Melbourne and started a PhD with us in 2014 studying ADCC immunity to influenza. She has studied ADCC immunity to internal influenza proteins, to H7N9 pandemic influenza and in response to vaccination of the elderly.
Joshua Glass
Josh completed a combined Bachelor of Commerce and Bachelor of Science degree with Honours at the University of NSW in 2013 where he was awarded a series of medals and commendations. He has worked as a research assistant at the Garvan Insitute in Sydney before taking up a PhD position with us in early 2014. He is studying nanoparticle-based HIV vaccines as part of a large collaborative ARC Centre of Excellence award. He is collaborating widely across the 19 CIs in this Centre, becoming an expert in studying how nanoparticles interact with immune cells.
Hannah Kelly
Hannah is a "Kiwi" who graduated from Victoria University of Wellington. She joins our group after working as a research assistant at Absynth Biologics Ltd, Sheffield in the UK. She is planning on working on projects related to understanding how nanoparticles interact with immune cells and could function as vaccines.
Julius Wong
Julius is planning to start a PhD with us early 2017 on influenza immunity projects.
Administrative Assistant
Jane Batten
Jane is a former research scientist who worked with us for many years prior to having children. She rejoined the group part time in 2015 to help us manage our large research enterprise.
See Stephen's Lab Blog for 2009-March 2014
See Stephen's Lab Blog for April 2014-December 2016
June 2017
Lots of papers coming out recently – see the publications page - so many that we had to have a combined celebration with some special champagne. Things got a little out of hand, formula 1 podium style. See our Instagram site for a small flavour. Congratulations to all the authors. A special mention to Matt for the Science Translational Medicine paper.
Taking a breather from NHMRC program and fellowship grants at present, whew. Jane has been a big help getting our program grant application in. Sinth and Adam are battling project grant reviewers at present. The NHMRC system is changing substantially next year.
A big welcome to Timon from Germany who is starting a PhD with Amy. Sinth has also formally joined our group and has lots of Flu ideas as ever. We have a new vet Clare who will be helping with the animal facility. A teary goodbye to Fernanda – she's finished her PhD (assuming reviewers are kind!) and off to San Diego for more adventures! Josh is writing up and Hillary will be next to write up!
Stephen at the Keystone HIV Vaccines meeting in Colorado
Anna Schorcht, who spent a few months with us, is now doing a PhD in HIV vaccines in Amsterdam! Proud that we didn't turn her off science and HIV!
April 2017 PhD Graduations
February 2017
Our expanded lab seems to be holding together. We are running out of desk and lab space but the department is thinking about ways to find us all some more space. Kathleen, Ester, Robyn, and Julius are all settling in and Timon will be starting soon. We were sad to see Milla head off to medical school. Vijaya has started a post-doc with Jamie Rossjohn's group at Monash and we wish her well also (while she pulls together resubmissions of her last 2 papers!).
Matt is in Canada doing some work with Andrés Finzi's group in Montreal. Kevin, Wen Shi and Kuangyu took some well-deserved time off for Chinese New Year. We've had some big bleed days lately with plenty of samples – well done to Vinca, Thakshila, Jen, Anne and everyone for pitching in to help. See our instagram site @kentlaboratory for some shots of the lab. Josh and Fernanda both sailed through various PhD committee meetings recently. Stephen and Jane have been busy submitting grants – ugh. More to come alas.

subset: commoncrawl


text:
Tag: Ahmed
Sort: Date | Views | Likes | Random Sort Ascending
770 Views0 Comments7 Likes
Ahmed Is A Soccer Jock From New Orleans. He'd Gone To A Party Right After One Of His Games Last Weekend And Decided He'd Celebrate His Team Victory Yuck Boys Style! He's Never Been With Another Black Guy Before, And ...